Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?
about
Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxiaUnderstanding the genetic and molecular pathogenesis of Friedreich's ataxia through animal and cellular modelsTherapeutic developments in Friedreich ataxiaTransition metals and mitochondrial metabolism in the heartMitochondria as a therapeutic target in heart failureLimitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screenIron-binding activity in yeast frataxin entails a trade off with stability in the alpha1/beta1 acidic ridge regionCombined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.Past, present and future therapeutics for cerebellar ataxias.Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities.Small molecules affecting transcription in Friedreich ataxiaCardiomyopathy of Friedreich's ataxia: use of mouse models to understand human disease and guide therapeutic development.The Heart in Friedreich's Ataxia: Basic Findings and Clinical Implications.A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse modelPCTH: a novel orally active chelator for the treatment of iron overload disease.The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation.Iron out-of-balance: a risk factor for acute and chronic diseases.Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxiaCurrent and emerging treatment options in the management of Friedreich ataxia.Cardiomyopathy of Friedreich ataxia.Human mitochondrial ferritin improves respiratory function in yeast mutants deficient in iron-sulfur cluster biogenesis, but is not a functional homologue of yeast frataxin.
P2860
Q24323371-D9C2F164-7CB0-4A3F-8D3A-9BCF71EF97F3Q26860523-F9140535-527A-428D-93B8-D0915D3CB14AQ26861733-A4019300-A510-4468-9082-472102D4934CQ26999334-FD8949CF-0D78-484E-9112-F1ACB796B39FQ27005632-149C37AA-CB90-43EB-BB8C-684772C8906CQ33496330-D5C900FD-CB3A-4506-8655-43E6B67D7049Q33643445-0070434A-40F6-4562-A76D-78B9E2FC0093Q33701891-483A41BD-849A-4702-828D-BEB60D3EA0F9Q33836935-1295B56E-F7DE-4257-90AA-31FB88EA251FQ34076650-81B20940-3212-40EF-9CD9-5B0D4838B789Q34582710-FC81CE9A-4B61-4AE6-8BD4-1DBAE8DC755BQ34989407-C555B428-3A97-4B2D-ADA0-20887F7804ECQ35052617-69F67E71-9867-4BCF-8A51-4CBA584A244CQ35770976-AE4CEA23-3CF1-442A-A39A-8E641FE7AF92Q36422479-38403677-0AA3-4799-981E-D2A66971885AQ36775301-6FE64A6B-8771-4855-90BF-1871B63B3CF7Q37084723-8AF656CB-8D34-4241-B22B-E8AC27AD0301Q37686297-43CE19B2-CE5E-498A-B915-CE774A561774Q37790615-CECBC267-5DD6-402C-9991-00BA8F6D1D32Q38121946-AC57A76D-6B42-42C4-A74C-4082800E5C22Q42321003-F45B9989-15A9-4CE9-ABAE-3F0A72BE767D
P2860
Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Friedreich's ataxia: iron chel ...... ion as a therapeutic strategy?
@ast
Friedreich's ataxia: iron chel ...... ion as a therapeutic strategy?
@en
type
label
Friedreich's ataxia: iron chel ...... ion as a therapeutic strategy?
@ast
Friedreich's ataxia: iron chel ...... ion as a therapeutic strategy?
@en
prefLabel
Friedreich's ataxia: iron chel ...... ion as a therapeutic strategy?
@ast
Friedreich's ataxia: iron chel ...... ion as a therapeutic strategy?
@en
P2860
P1476
Friedreich's ataxia: iron chel ...... ion as a therapeutic strategy?
@en
P2093
Richardson DR
P2860
P304
P356
10.1517/13543784.12.2.235
P407
P577
2003-02-01T00:00:00Z